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Abstract
Background: The synthesis of published research in systematic reviews is
essential when providing evidence to inform clinical and health policy decision-
making. However, the validity of systematic reviews is threatened if journal
publications represent a biased selection of all studies that have been conducted
(dissemination bias). To investigate the extent of dissemination bias we conducted
a systematic review that determined the proportion of studies published as peer-
reviewed journal articles and investigated factors associated with full publication in
cohorts of studies (i) approved by research ethics committees (RECs) or (ii)
included in trial registries.
Methods and Findings: Four bibliographic databases were searched for
methodological research projects (MRPs) without limitations for publication year,
language or study location. The searches were supplemented by handsearching
the references of included MRPs. We estimated the proportion of studies published
using prediction intervals (PI) and a random effects meta-analysis. Pooled odds
ratios (OR) were used to express associations between study characteristics and
journal publication. Seventeen MRPs (23 publications) evaluated cohorts of studies
approved by RECs; the proportion of published studies had a PI between 22% and
72% and the weighted pooled proportion when combining estimates would be
46.2% (95% CI 40.2%–52.4%, I2594.4%). Twenty-two MRPs (22 publications)
evaluated cohorts of studies included in trial registries; the PI of the proportion
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published ranged from 13% to 90% and the weighted pooled proportion would be
54.2% (95% CI 42.0%–65.9%, I2598.9%). REC-approved studies with statistically
significant results (compared with those without statistically significant results) were
more likely to be published (pooled OR 2.8; 95% CI 2.2–3.5). Phase-III trials were
also more likely to be published than phase II trials (pooled OR 2.0; 95% CI 1.6–
2.5). The probability of publication within two years after study completion ranged
from 7% to 30%.
Conclusions: A substantial part of the studies approved by RECs or included in
trial registries remains unpublished. Due to the large heterogeneity a prediction of
the publication probability for a future study is very uncertain. Non-publication of
research is not a random process, e.g., it is associated with the direction of study
findings. Our findings suggest that the dissemination of research findings is biased.
Introduction
The synthesis of published research in systematic reviews is essential when
providing evidence to inform both clinical and health policy decision making.
However, its validity is threatened if publications represent a biased selection of all
the studies that have been conducted. Publication bias occurs when some types of
results (e.g., those that are statistically significant) are reported more frequently or
more quickly than others. [1–3] Increasingly, the term dissemination bias is used.
It reflects that research reporting is not limited to journal publication alone but
also comprises other forms of dissemination such as posting results in a trial
registry. [4] Dissemination bias, similar to publication bias, results from favoured
dissemination of research findings depending on their statistical significance and
direction. It may lead to preferential prescribing of newer and more expensive
treatments while underestimating the potential harm of drugs that have been in
use for only a limited time. Clinical decisions may, therefore, be based on
erroneous information. [5] It is obvious that these selection mechanisms violate
the fundamental scientific and ethical imperative that findings from all research
on humans should be available to advance knowledge. Furthermore, non-
publication of studies implies considerable financial investment by funders
without any return. Further down the road, indirect costs incurred due to non-
publication of studies include those by health care providers, health insurances,
and patients who all continue to pay for treatments that may not be the most
effective ones or may even be harmful.
In response to these concerns, the OPEN Project (To Overcome failure to
Publish nEgative fiNdings; www.open-project.eu) was developed with the goal of
elucidating the scope of non-publication of studies through a series of systematic
reviews and to develop recommendations. [4, 6–8] The OPEN Project was funded
by the European Commission and conducted by an international working group
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of methodologists and other experts (see S1 Fig.). Besides evaluating the extent of
non-publication of studies, OPEN examined current publication practices of key
groups in the field of biomedical research (e.g., funding agencies, pharmaceutical
industry, research ethics committees [RECs], trial registries, biomedical journals
and regulatory agencies) through surveys and analysis of current policies and
guidelines.
Because unpublished studies are hidden from view it is challenging to study
dissemination bias. [9] One opportunity for such research is that in virtually all
research settings REC approval is required before clinical studies can start. In
addition, an increasing number of journals require prospective trial registration as
a pre-condition for acceptance of manuscript reporting on studies. Further, any
clinical study conducted under FDA regulations in the United States needs to be
registered in clinicaltrials.gov (http://clinicaltrials.gov/ct2/manage-recs/
fdaaa#WhichTrialsMustBeRegistered). Thus, study protocols submitted to RECs
and study data accessible in trial registries are a resource to identify unpublished
studies and evaluate the extent of non-publication of clinical research.
This systematic review investigated the extent to which studies approved by
RECs or included in trial registries remained unpublished. To this effect, evidence
from methodological research projects (MRPs) following such studies was
evaluated and summarised. In addition, we assessed study characteristics that are
potentially associated with publication (dissemination bias). The review was
conducted according to a protocol published previously. [6]
Methods
Systematic literature search
We searched the databases Medline (Ovid), Embase (Ovid), The Cochrane Library
and Web of Science from their inception until February 2012. An update search
was performed in November 2013. The search strategy was based on combinations
of medical subject headings (MeSH) and keywords and was not restricted to
specific languages or years of publication. The search strategy used in Medline
(Ovid) is presented in S2 Fig. Search strategies for other databases were adapted
to meet the requirements of each database while keeping the search algorithm.
The searches were supplemented by checking the bibliographies of any eligible
articles for additional references. In addition, several experts in the field were
contacted and asked to identify additional studies.
Study selection and inclusion criteria
Titles and abstracts were reviewed using specific inclusion criteria (see below). All
stages of study selection, data extraction and quality assessment were done
independently by two reviewers (CS, LC, PO, LKS). Any disagreement during the
selection, extraction, and assessment process was resolved by discussion and
consensus.
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We included MRPs which reported the proportion of studies published as
journal publication after (i) REC approval or (ii) inclusion in trial registries.
MRPs evaluating approved studies were included under the assumption that the
majority of those studies were completed at the time of the search for peer-
reviewed journal publications. In the case of multiple publications we extracted
data from the MRP with the largest sample size and/or most comprehensive
information while using cross-referencing.
Outcomes
Our main outcomes were the overall proportion of studies published as journal
articles and time to journal publication after study completion. Thereby, study
completion was defined as the last day of follow-up of study participants. If the
last day of follow-up was not given, time to publication was calculated based on
the time reported in the MRP. To calculate the overall proportion of studies
published, we set a minimum follow-up time of 24 months after study
completion. In addition, we aimed to identify study characteristics that were
associated with an increased likelihood of journal publication and time to
publication. [6] We also collated information on costs or other resources which
occurred by studies that were not published (if available). For the evaluation of
study associations with publication a minimum follow-up time after study
completion was not necessary. Outcomes were reported separately for both types
of MRPs (RECs and trial registries).
Data extraction and risk of bias assessment
Information on main characteristics of studies were abstracted for each MRP. [6]
Internal and external validity of the identified MRPs was evaluated according to
pre-defined criteria which were developed considering relevant literature
investigating dissemination bias [10] and internal discussion. [6] Criteria for
internal validity were: (i) follow-up time between study completion and search for
journal publication, (ii) methodology used to identify journal publications, (iii)
matching between study protocol or trial registry entry and retrieved journal
publication and (iv) adjustment for confounders. External validity was judged
based on the status of the study sample (i.e., whether the reported proportion of
studies published was calculated based on a sample of completed and/or approved
studies) and the sampling method used (i.e., whether a random or selected study
sample was considered).
For each criterion an MRP’s risk of bias was categorized as high, low or unclear.
Statistical analysis/data synthesis
For both types of MRPs (RECs and trial registries) we separately estimated the
proportion of studies published as journal articles using a random effects meta-
analysis (DerSimonian-Laird method) based on logit-transformed proportions
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and their corresponding 95% confidence intervals (CI). Heterogeneity was
assessed with the Chi2-test and calculation of the I2 statistic. [11] Given the
substantial heterogeneity found we also decided to calculate prediction intervals
(PI) - which were not pre-specified in the published protocol - using the method
suggested by Higgins et al. [12] Pooled odds ratios (OR) were used to express
associations between study characteristics and the likelihood of journal
publication. Multivariate analyses of study characteristics were not feasible due to
the small number of studies providing this information.
To address potential bias due to approved rather than completed studies, the
status of the study sample (completed, on-going and/or approved) was evaluated
within a sensitivity analysis.
Time to publication was analysed in two ways: (i) Mean or median time was
used only if the proportion of studies published as peer-reviewed journal articles
was larger than 50%. Some MRPs calculated time to publication from approval of
studies to journal publication, others from study completion to journal
publication. Due to these differences in definitions we refrained from pooling
time-to-publication estimates. (ii) The proportion of studies published up to fixed
time points (e.g., 6, 12, 18, 24, 36 months) was extracted from included MRP
publications (e.g., from published Kaplan Meier curves). For each time point we
performed a random-effects meta-analysis using logit-transformed proportions.
Statistical analyses were done with R using the meta package (http://cran.r-
project.org/web/packages/meta/index.html).
Results
Results of literature search and selection process
The searches identified 8612 references, including 2468 duplicates (Fig. 1).
Among the 6144 potentially relevant references, 39 MRPs (45 publications) were
eligible for the systematic review: 17 reported on MRPs following studies
approved by RECs [13–29] (23 publications) [9, 13–34] and 22 on MRPs [35–56]
following studies included in trial registries (22 publications).
Characteristics of included MRPs
The main characteristics of included MRPs of both types are presented in Table 1
and Table 2.
MRPs following studies after REC approval
Of the 17 MRPs that followed studies approved by RECs, four focused on specific
medical fields: psychology, [15] epidemiology, [16] paediatrics [24] and general
medicine [29]. Eight [17, 19–21, 23, 26–28] included studies from different fields
and five [13, 14, 18, 22, 25] did not provide any information. Two MRPs [14] [28]
included solely randomised controlled trials and 15 allowed for a wide range of
interventional and observational study designs. The RECs in charge of study
approval were based in Germany, [13, 21] USA, [15, 18, 27] The Netherlands, [16]
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Fig. 1. PRISMA statement flow diagram.
doi:10.1371/journal.pone.0114023.g001
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Table 1. Main characteristics of 17 methodological research projects following studies after approval by a research ethics committee.
Reference Medical field
Country of
REC(s) Included study sample
Methodology used to
identify journal
publications
Minimal time from
approval/
completion to
search for journal
publication
(months)
No of selected
studies
No of
published
studies
(%)
Blu¨mle 2014
[13, 30, 31]
Not reported Germany All initiated human research
studies approved by REC of
the University of Freiburg
(Germany) between 2000
and 2002 (studies of all
designs)
Electronic database
search, author contact
(90% response rate)
104 (from approval) 807 419
(51.9)
Chan 2004
[14]
Not reported Denmark RCTs approved by the
Scientific-Ethical Committees
for Copenhagen &
Frederiksberg (Denmark) in
1994–1995 (RCTs)
Electronic database
search, author contact
(55% response rate)
.24 months* (from
approval)
274 102
(37.2)
Cooper 1997
[15]
Psychology USA Studies approved by the
Department of Psychology
Human Subjects Committee
during the years 1986/87 and
1987/88 (study design not
given)
Authors contact (100%
response rate)
.24 months*(from
approval)
159 41 (25.8)
De Jong
2010 [16]
Epidemiology The
Netherlands
Random sample of approved
protocols of epidemiological
studies clinical trials between
1997 and 2006 (interventio-
nal+observational studies)
Electronic database
search, author contact
(100% response rate)
.24 months* (from
approval)
80 23 (28.8)
Decullier
2005 [17, 32]
Different medi-
cal specialties
France Completed research proto-
cols which had been
approved in 1994 by a ran-
dom sample of French com-
mittees (study design not
given)
Author contact (100%
response rate)
.24 months* 501 190
(37.9)
Dickersin
1992 [18, 33]
Not reported USA Studies approved in 1980 or
prior by 2 institutional review
boards (observational+ex-
perimental studies)
Authors contact (100%
response)
96 (from approval) 514 390
(75.9)
Easterbrook
1992 [9, 19]
Different medi-
cal specialties
UK Research protocols
approved/completed by the
Central Oxford REC between
1984 and 1987 (RCT+others)
Author contact (100%
response)
29 (from comple-
tion)
285 (completed)/
487 (approved)
138 (48.2)/
209
(43.0)
Hall 2007 [20] Different medi-
cal specialties
Canada All protocols submitted to the
Capital District Health
Authority Research Ethics
Board for the period 1995–96
(RCTs+others)
Electronic database
search, author contact
(response rate not
given)
.24 months* (from
approval)
190 84 (44.2)
Menzel 2007
[21]
Different medi-
cal specialties
Germany Clinical trials approved in
1996 (study design not given)
Electronic database
search
.24 months* (from
approval)
99 71 (71.7)
Olofsson
2000 [22]
Not reported Sweden All approved projects in 1992
(study design not given)
Electronic database
search, author contact
(response rate not
given)
72 (from approval) 133 58 (43.6)
Pich 2003
[23]
Different medi-
cal specialties
Spain Clinical trials submitted in
1997 to REC (study design
not given)
Author contact
(response rate not
given)
.24 months* from
approval)
123 26 (21.1)
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Denmark, [14] France, [17] United Kingdom, [19, 29] Canada, [20] Sweden, [22]
Spain, [23, 26] Argentina, [24] Australia [25] and Switzerland. [28]
MRPs following studies after inclusion in trial registries
Of the 22 MRPs following studies included in trial registries, 12 focused on
specific medical fields: orthopaedics, [36, 46] pneumology, [38] ophthalmology,
[40] oncology, [41] neurology, [44] gynecology, [47] rheumatology, [51] urology,
[53] pediatrics, [52] orthopedics [54] and gastroenterology/hepatology [45]. One
MRP included drug trials in internal medicine and psychiatry [35] and another
was restricted to Chinese trials dealing with different medical specialties. [39]
Three MRPs did not restrict their field of research [37, 42, 43] and five did not
provide any information. [48–50, 55, 56] Seven MRPs included randomised
controlled trials. [44–46, 50, 51, 56] The remaining MRPs either did not specify
included study designs or included a wide range of designs ranging from
Table 1. Cont.
Reference Medical field
Country of
REC(s) Included study sample
Methodology used to
identify journal
publications
Minimal time from
approval/
completion to
search for journal
publication
(months)
No of selected
studies
No of
published
studies
(%)
Rodriguez
2009 [24]
Pediatrics Argentina Approved protocols between
01/2001 and 06/2006
(observational studies+-
others)
Author contact
(response rate not
given)
.24 months* (from
approval)
125 40 (32)
Stern 1997
[25]
Not reported Australia A cohort of studies submitted
between 09/1979 and 12/
1988 to a hospital ethics
committee (RCT+others)
Author contact (100%
response)
42 (from comple-
tion)
321 189
(58.9)
Sune 2013
[26, 34]
Different medi-
cal specialties
Spain Completed or prematurely
terminated drug-related clin-
ical trials approved by a
general hospital ethics com-
mittee between 1997 and
2004 (controlled and uncon-
trolled studies)
Database search .24 months* (from
completion)
785 380
(48.4)
Turer 2007
[27]
Different medi-
cal specialties
USA All prospective, multicenter
clinical trials of treatment
approved in 1998 (observa-
tional studies excluded)
Electronic database
search, author contact
(response rate not
given)
.24 months* (from
approval)
197 101
(51.3)
Von Elm
2008 [28]
Different medi-
cal specialties
Switzerland Clinical studies of drug inter-
ventions submitted and com-
pleted to REC from 1988 to
1998 (RCTs)
Electronic database
search, author contact
(response rate not
given)
.24 months* (from
completion)
451 233
(51.7)
Wise 1996
[29]
General
Medicine
UK First 100 consecutive proto-
cols submitted and com-
pleted after establishment of
REC by pharmaceutical
companies (study design not
given)
Contacted pharmaceu-
tical companies/inves-
tigators (100%
response)
.24 months* (from
completion)
68 30 (44.1)
*No definite follow-up time predictable, but more than 24 months follow-up from study approval or completion to search for full publication fulfilled.
RCT: randomised controlled trial, REC: research ethic committee.
doi:10.1371/journal.pone.0114023.t001
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Table 2. Main characteristics of 22 methodological research projects following studies included in trial registries.
Reference Medical field Trial registry Included study sample
Methodology
used to
identify
journal
publications
Minimal time from
registration/
completion to search
for journal publication
(months)
No of
selected
studies
No of
published
studies
(%)
Bourgeois
2010 [35]
Drug trials/internal
medicine and psy-
chiatry
clinicaltrials.gov Safety and efficacy trials con-
ducted and completed
between 2000 and 2006
(observational studies+others)
Electronic
database and
trial registry
search, author
contact
39 (from completion) 546 362
(66.3)
Chahal
2012 [46]
Orthopaedic sports
medicine
clinicaltrials.gov All RCTs related to sports
medicine closed and com-
pleted by 06/2009 (RCTs)
Electronic
database and
trial registry
search
33 (from completion) 34 20 (58.8)
Gandhi
2011 [36]
Orthopaedic trau-
matology
clinicaltrials.gov Interventional trials related to
orthopaedic trauma registered
and completed up to 07/2009
(study design not given)
Electronic
database and
trial registry
search
.24 months* (from
completion)
37 21 (56.8)
Gopal 2012
[37]
Different medical
specialties
clinicaltrials.gov Completed interventional stu-
dies that may be subject to
FDA regulation, 1 year prior to
required results reporting (10/
2006 to 09/2007) and during 2
years after required reporting
(10/2007 to 09/2009) (study
design not given)
Electronic
database and
trial registry
search
25 (from completion) 818 185
(22.6)
Guo 2013
[47]
Gynecology clinicaltrials.gov Interventional trials on endo-
metriosis completed by 01/
2012 (study design not given)
Electronic
database
search
24 month follow-up not
fulfilled, but included to
derive associations with
full publications
27 5 (14.3)
Hurley
2012 [38]
Cystic fibrosis
(pneumology)
clinicaltrials.gov Completed interventional trials
between 01/1998 and 12/2010
(study design not given)
Electronic
database
search, author
contact
24 month follow-up not
fulfilled, but included to
derive associations with
full publications
142 75 (52.8)
Huser 2012
[48]
Not reported clinicaltrials.gov Random sample of trials com-
pleted between 09/2004 and
12/2008 with no linked publi-
cation (study design not given)
Electronic
database
search, author
contact
36 (from completion) 50 22 (44.0)
Huser 2013
[49]
Not reported clinicaltrials.gov Completed interventional trials
between 01/2006 and 12/2009
(Phase-2 studies)
Electronic
database and
trial registry
search
38 (from completion) 8907 2477
(27.8)
Jones 2013
[50]
Not reported clinicaltrials.gov Large (.500 patients) studies
that were prospectively regis-
tered and closed prior to 01/
2009 (RCTs)
Electronic
database and
trial registry
search, author
contact
46 (from completion or
closed trials) (minimal
follow-up)
513 381
(74.3)
Khan 2012
[51]
Rheumatology clinicaltrials.gov Trials of drug therapy for rheu-
matoid arthritis of phase 2 or
higher and completed between
2002–2003 or between 2006–
2007 (RCTs)
Electronic
database and
trial registry
search
Follow-up not given, but
included to derive asso-
ciations with full publica-
tions/or sensitivity
analysis
62 42 (67.7)
Liu 2010
[39]
Different medical
specialties
clinicaltrials.gov
and 10 WHO
registries
Completed Chinese interven-
tional trials (observational stu-
dies+others)
Electronic
database and
trial registry
search, author
contact
24 month follow-up not
fulfilled, but included to
derive associations with
full publications
443 156
(35.9)
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Table 2. Cont.
Reference Medical field Trial registry Included study sample
Methodology
used to
identify
journal
publications
Minimal time from
registration/
completion to search
for journal publication
(months)
No of
selected
studies
No of
published
studies
(%)
Prenner
2011 [40]
Ophthalmology clinicaltrials.gov Completed interventional trials
(study design not given)
Electronic
database
search
.24 months* (from
completion)
64 35 (54.7)
Ramsey
2008 [41]
Oncology clinicaltrials.gov Interventional trials designated
as either completed or termi-
nated in 09/2007
(RCTs+others)
Electronic
database and
trial registry
search
24 month follow-up not
fulfilled, but included to
derive associations with
full publications
2028 357
(17.6)
Ross 2009
[42]
Different medical
specialties
clinicaltrials.gov Clinical trials registered after
01/2000 and updated as hav-
ing been completed by 01/
2006 excluding phase I trials
(observational studies+others)
Electronic
database and
trial registry
search, author
contact
.24 months* (from
completion)
677 311
(46.0)
Ross 2012
[43]
Different medical
specialties
clinicaltrials.gov Interventional trials funded by
NIH registered after 09/2005
and updated as having been
completed by 01/2009 (study
design not given)
Electronic
database and
trial registry
search
26 (from completion) 635 432
(68.0)
Shamliyan
2012 [53]
Urology clinicaltrials.gov Completed or discontinued
trials of drug therapies or non-
surgical treatments for women
with urinary incontinence
(interventional+observational
studies)
Electronic
database and
trial registry
search
.24 months* (from
completion)
112 26 (23.2)
Shamliyan
2012 [52]
Pediatrics clinicaltrials.gov Random sample of completed
pediatric trials (interventional
+observational studies)
Not reported 24 month follow-up not
fulfilled, but included to
derive associations with
full publications
758 218
(28.8)
Smith 2012
[54]
Orthopaedics clinicaltrials.gov Closed RCTs on arthroplasty
with an estimated completion
date up to 07/2009 (RCTs)
Electronic
database and
trial registry
search
24 month follow-up not
fulfilled, but included to
derive associations with
full publications or sen-
sitivity analysis
101 23 (22.8)
Tfelt-
Hansen
2011 [44]
Neurology GSK trial registry RCTs (double-blind) concern-
ing the use of naratriptan in
migraine (RCTs)
Search in GSK
registry
Follow-up not given, but
included to derive asso-
ciations with full publica-
tions or sensitivity
analysis
17 11 (64.7)
Thorn 2013
[55]
Not reported ISRCTN register RCTs planning an economic
evaluation with an anticipated
end before 01/2008 (RCTs)
Electronic
database and
trial registry
search, authors
contact
.24 months* (from
completion)
100 70 (70.0)
Vawdrey
2013 [56]
Not reported clinicaltrials.gov Clinical trials of electronic
health records completed by
2009 (study design not given)
Electronic
database and
trial registry
search, author
contact
.24 months* (from
completion)
62 47 (75.8)
Wildt 2011
[45]
Gastroenterology,
Hepatology
clinicaltrials.gov RCTs (phase III) on adult
patients with gastrointestinal
diseases initiated or completed
during 1998 and 2008 (RCTs)
Electronic
database
search
.24 months* (from
initiation or completion)
105 66 (62.9)
*No definite follow-up time predictable, but more than 24 months follow-up from study completion to search for full publication fulfilled.
FDA: US Food and Drug Administration, GSK: Glaxo Smith Kline, ISRCTN: International Standard Randomised Controlled Trial Number, NIH: National
Institutes of Health, RCT: randomised controlled trial, WHO: World Health Organisation.
doi:10.1371/journal.pone.0114023.t002
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observational studies to controlled clinical trials. Twenty [35–43, 45–54, 56] of the
22 MRPs searched www.clinicaltrials.gov. Besides clinicaltrials.gov one MRP also
searched 10 WHO registries for Chinese trials, [39] two other MRPs searched the
GlaxoSmithKline (GSK) trial registry (United Kingdom) [44] and the ISRCTN
register, [55] respectively.
Risk of bias
Results of the methodological quality assessment are presented in Table 3 and
Table 4, respectively.
MRPs following studies after REC approval
All of the included MRPs fulfilled the 24-month follow-up criterion. However,
twelve MRPs based their follow-up time on studies which were approved but not
necessarily completed. [13–16, 18, 20–25, 27] Although these MRPs fulfilled the
24-month follow-up criterion, we judged them to have an unclear risk of bias. The
methodology used to identify journal publications was adequate in all but two
MRPs. [23, 24] Three MRPs performed adequate matching between protocol and
retrieved journal publications. [13, 26, 28] However, in most MRPs this criterion
was not applicable because identification of journal publications relied solely on
author contacts. None of the MRP publications reported on adjustment for
confounding factors when calculating proportions of published studies in specific
subgroups or calculating measures of association between likelihood of
publication and subgroup characteristics.
MRPs following studies after inclusion in trial registries
Fourteen MRPs following studies included in trial registries had a follow-up time
between study completion and search for full publication of 24 months or more.
[35–37, 40, 42, 43, 45, 46, 48–50, 53, 55, 56] All but one [45] of these MRPs
included cohorts of completed studies. The publication status was verified by
searching adequate electronic databases and/or contacting the lead investigators in
all but two MRPs. [44, 52] Thirteen MRPs
[35, 37, 38, 40, 41, 44, 45, 48, 49, 52, 53, 55, 56] did not comment on matching
criteria between registry entry and retrieved journal publication; whereas all but
one [47] remaining MRPs performed adequate matching. Similar to MRPs
following studies after REC approval, adjustment for confounders was not
considered in any of the MRPs.
Proportion of studies published
After REC approval, the proportion of studies published ranged from 26% to 76%
in 17 MRPs with a follow-up of 24 months or more, including 5112 studies
(Fig. 2, Table 5). The prediction interval was 22% to 72%; the heterogeneity
among individual estimates was substantial (I2594.4%, p,0.0001). If one
combined the individual estimates even so the pooled estimate would be 46.2%
(95% CI 40.2–52.4).
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After trial registration, the proportion of studies published ranged from 23% to
76% in 14 MRPs with a follow-up of 24 months or more, including 12660 studies
(Fig. 3, Table 5). The prediction interval was 13% to 90%; again the heterogeneity
among individual estimates was substantial (I2598.9%, p,0.0001). If one
combined the individual estimates even so the pooled estimate would be 54.2%
(95% CI 42.0–65.9).
In a sensitivity analysis we excluded those MRPs that were based on a cohort of
approved [13–16, 18, 20–25, 27] or initiated [45] studies. In the resulting sample
of completed studies a pooled proportion of studies published would be similar:
46.3% (95% CI 41.0–51.6; I2581.1%, p,0.0001; based on five MRPs following
Table 3. Risk of bias table for MRPs following studies after approval by a REC.
Internal validity External validity
follow-up time
between study
completion and
search for journal
publication
methodology used
to identify journal
publications
matching between
REC protocol and
journal publication
adjustment
for
confounders
research status of
REC protocol
(e.g., approved or
completed trial)
sampling method
(e.g., all trials,
random
sample)
Blu¨mle 2014 [13, 30, 31] ? + + - - -
Chan 2004 [14] ? + ? - - ?
Cooper 1997 [15] ? + NA - - ?
De Jong 2010 [16] ? + ? - - +
Decullier 2005 [17, 32] + + NA - + +
Dickersin 1992 [18] [33] ? + NA - - +
Easterbrook 1992 [19] [9]* + + NA - + +
Hall 2007 [20] ? + - - - +
Menzel 2007 [21] ? + - - - ?
Olofsson 2000 [22] ? + ? - - +
Pich 2003 [23] ? ? NA - - ?
Rodriguez 2009 [24] ? ? NA - - ?
Stern 1997 [25] + + NA - - +
Sune 2013 [26] [34] + + + - + +
Turer 2007 [27] ? + ? - - +
Von Elm 2008 [28] + + + - + ?
Wise 1996 [29] + + NA - + +
*Easterbrook 1992 reported publication rates for completed and approved studies separately. We just refer to the completed sample in this review. NA: Not
applicable.
+ means low risk of bias; - means high risk of bias;? means unclear risk of bias.
Follow-up time:.24 months after study completion: +. ,24 months follow-up after study completion: -. MRPs which judged their follow- up rather on
approved than completed studies. Although these MRPs fulfilled the 24 month follow-up criteria, we judged them to have an unclear risk of bias:?.
Methodology used to identify journal publication: electronic search and author contact: +. only author contact (with response rate of $80%): +. only
author contact (with response rate ,80%): -; only database search (in 1 database): -. only database search (in.1 database): +. methodology not given:?.
Adjustment for confounders: if an analysis for factors associated with journal publication was carried out: +. if no analysis was carried out: -.
Matching criteria: if $2 matching criteria given: +. if ,2 matching criteria given: -. matching criteria not given in MRP:?. if only author contact was used to
identify journal publication: NA (not applicable).
Research status: completed protocols: +. approved protocols: -.
Sampling method: all trials, random sample or consecutive trials: +. if only investigator responded to questionnaire for this sample: -. sampling method not
given (e.g., without the word ‘‘all’’):?.
doi:10.1371/journal.pone.0114023.t003
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studies after REC approval) [17, 19, 26, 28, 29] and 53.5% (95% CI 40.9–65.7;
I2598.9%, p50.0003; based on 13 MRPs following studies after inclusion in trial
registries) [35–37, 40, 42, 43, 46, 48–50, 53, 55, 56], respectively. The sensitivity
analysis of MRPs which only included randomised controlled trials would yield a
pooled proportion of published studies of 44.5% (95% CI 31.0–58.8; I2592.9%,
p50.0002; based on two MRPs following studies after REC approval) [14, 28] and
60.3% (95% CI 45.4–73.6; I2592.5%, p,0.001; based on seven MRPs following
Table 4. Risk of bias table for MRPs following studies included in trial registries.
Internal validity External validity
follow-up time between
study completion and
search for journal
publication
methodology
used to identify
journal
publications
matching
between
registry entry
and journal
publication
adjustment
for
confounders
research status of
registry entry
(e.g., completed or
ongoing trial)
sampling method
(e.g., all trials,
random
sample)
Bourgeois 2010 [35] + + ? - + +
Chahal 2012 [46] + + + - + +
Gandhi 2011 [36] + + + - + +
Guo 2013 [47] - - - - + +
Gopal 2012 [37] + + ? - + +
Hurley 2012 [38] - + ? - + +
Huser 2012 [48] + + ? - + +
Huser 2013 [49] + + ? - + +
Jones 2013 [50]* + + + - + +
Khan 2012 [51] ? + + - + +
Liu 2010 [39] - + + - + +
Prenner 2011 [40] + - ? - + +
Ramsey 2008 [41]* - + ? - + +
Ross 2009 [42] + + + - + +
Ross 2012 [43] + + + - + +
Shamliyan 2012a [53]* + + ? - + +
Shamliyan 2012b [52] - ? - + +
Smith 2012 [54] - + + - + +
Tfelt-Hansen 2011 [44]** ? - ? - ? +
Thorn 2013 [55] + + ? - + +
Vawdrey 2013 [56] + + ? - + +
Wildt 2011 [45] + ? - -
*The research status of Shamliyan 2012a refers to completed and terminated trials.
**The MRP of Tfelt-Hansen 2011 is based on the GKS registry only.
+ means low risk of bias; - means high risk of bias;? means unclear risk of bias.
Follow-up time:.24 months: +. ,24 months: -. follow-up time not given/or could not be estimated:?.
Methodology used to identify journal publication: electronic search and author contact and/or search in trial registry: +. only author contact (with a
response rate of $80%): +. only author contact (with a response rate ,80%): -. only search in trial registry or only 1 database: -. methodology not given:?.
Adjustment for confounders: if an analysis for factors associated with the journal publication was carried out: +. if no analyses were carried out: -.
Matching criteria: if $2 matching criteria given: +. if ,2 matching criteria given: -. matching criteria not given in MRP:?.
Research status: completed registry entries: +. completed and initiated mixed: -. not mentioned:?.
Sampling method: all trials, random sample or consecutive trials: +. if only investigator responded to questionnaire for this sample: -. sampling method not
given (e.g., without the word ‘‘all’’):?.
doi:10.1371/journal.pone.0114023.t004
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studies after trial registration), respectively. [44–46, 50, 51, 54, 55] It should be
noted that three of these MRPs had insufficient follow-up time for searching full
publications [44, 51, 54] or included on-going studies. [45]
Factors associated with publication
Table 6 summarizes factors associated with journal publication of studies. Four
MRPs following studies approved by RECs compared studies with statistically
significant results (p,0.05) and studies with non-significant results. [9, 18, 25, 26]
Fig. 2. Weighted proportion of published studies for 17 MRPs following studies after REC approval.
doi:10.1371/journal.pone.0114023.g002
Table 5. Pooled proportions of published studies based on methodological research projects.
MRP category No of MRPs
Weighted proportion of
studies published (95% CI)
Heterogeneity test: I2 (p value
Chi2 test) Prediction Interval
RECs [9, 13–18, 20–29] 17 46.2% (40.2–52.4) 94.4% (,0.0001) 22% – 72%
Trial registries [35–37, 40, 42, 43, 45, 46, 48–
50, 53, 55, 56]
14 54.2% (42.0–65.9) 98.9% (,0.0001) 13%–90%
CI: Confidence interval, MRP: Methodological research project, No: Number, REC: Research ethics committee.
doi:10.1371/journal.pone.0114023.t005
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The pooled OR for publication of studies with statistically significant results (vs.
non-significant) was 2.8 (95% CI 2.2–3.5). Also studies with positive results
defined as experimentally better or clinically relevant had higher (but statistically
not significant) odds of journal publication than studies with negative results
(pooled OR 3.1; 95% CI 0.9–11.0; two MRPs). [25, 32]
Two of the MRPs that followed studies after REC approval [20, 30] and three of
the MRPs that followed studies after registration [39, 42, 43] investigated the
association of different study designs with publication (i.e., randomised controlled
trials versus observational studies). In both types of MRPs, randomised controlled
trials had a greater odds of publication than observational studies (OR 2.0; 95%
CI 1.3–3.3 and 1.2; 95% CI 1.0–1.5, respectively). A post-hoc analysis including
MRPs that followed studies after trial registration revealed that phase-III trials
were more likely to be published than phase-II trials (pooled OR 2.0; 95% CI 1.6–
2.5). [37, 38, 40–43, 47, 50, 52, 53]
In MRPs that followed studies after REC approval, multicentre studies were
more likely to be published than single centre studies (pooled OR 1.5; 95% CI
1.0–2.4; four MRPs). [18, 28, 30, 34] We also found that research funded by
governments was more frequently published than research funded by the industry
(pooled OR 2.2; 95% CI 1.7–2.9; eight MRPs following studies after trial
registration). [37, 39, 41, 42, 46, 50, 52, 53] But no difference in the probability of
publication between basic and human research was identified (pooled OR 1.1;
95% CI 0.6–2.1; two MRPs). [24, 30] There were also no significant differences for
Fig. 3. Weighted proportion of published studies for 14 MRPs following studies after trial registration.
doi:10.1371/journal.pone.0114023.g003
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national versus international studies (OR 1.3; 95% CI 0.5–3.8) in one MRP
following studies after inclusion in trial registries [40] and for studies with sample
sizes larger (versus smaller) than the cohort’s median sample size (OR 1.2; 95% CI
0.8–1.6) in another such MRP. [42] Other potential factors associated with
journal publications could not be derived from the included MRPs. In addition,
none of the MRPs reported on costs or use of other resources due to studies that
were not published.
Table 6. Factors associated with journal publication.
No of MRPs Pooled OR (95% CI) Heterogeneity test: I2 (p value of Chi2 test)
Significant vs non-significant results
RECs [9, 18, 25, 26] 4 2.8 (2.2–3.5) 0.0% (0.79)
Trial registries nr
Experimentally better vs not better results
RECs [25, 32] 2 3.1 (0.9–11.0) 76.9% (0.04)
Trial registries [56] 1 11.7 (2.8–48.5) - (2)
Phase III vs phase II studies
RECs [26] 1 1.5 (1.0–2.0) - (2)
Trial registries [37, 38, 40–43, 47, 50, 52, 53] 10 2.0 (1.6–2.5) 22.0% (0.24)
RCTs vs observational studies
RECs [20, 30] 2 2.0 (1.3–3.3) 0.0% (0.69)
Trial registries [39, 42, 43] 3 1.2 (1.0–1.5) 0.0% (0.78)
Basic vs human research
RECs [24, 30] 2 1.1 (0.6–2.1) 49.0% (0.16)
Trial registries nr
Multicentre vs single centre studies
RECs [18, 28, 30, 34] 4 1.5 (1.0–2.4) 49.0% (0.12)
Trial registries nr
National vs international
RECs [30] 1 1.1 (0.6–1.8) - (2)
Trial registries [40] 1 1.3 (0.5–38) - (2)
Funding vs no funding
RECs [18] 1 3.2 (2.0–5.2) - (2)
Trial registries nr
Government vs industry funding
RECs [26] 1 1.2 (0.8–1.9) - (2)
Trial registries [37, 39, 41, 42, 46, 50, 52, 53] 8 2.2 (1.7–2.9) 43.8% (0.09)
Sample size.vs sample size ,than median
RECs nr
Trial registries [42] 1 1.2 (0.8–1.6) - (2)
Nr: Not reported, MRP: Methodological research project, No: Number, OR: Odds ratio, REC: Research ethics committee.
doi:10.1371/journal.pone.0114023.t006
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Factors associated with time to publication
The time to full publication of studies being published in peer-reviewed journals
was reported in two MRPs following studies after REC approval: [17, 26] One
MRP [17] reported a statistically significant (p,0.001) association of the
direction of results with mean time to publication of 62.4 months (95% CI 57.6–
67.2) for positive (confirmatory) results compared with 78 months (95% CI 69.6–
86.4) for studies with inconclusive results and 82.2 months (95% CI 70.8–94.8)
for negative (invalidating) results. The second MRP [26] confirmed that the time
to publication is significantly associated with the direction of the results. Median
time to full publication was 25 months in studies with positive outcomes and 38.5
months in those with negative results.
Probability of publication over time
Three MRPs following studies approved by RECs provided information on the
time course of publication (Fig. 4): [16, 25, 30] after two years the publication
probability was approximately 7%, [16, 25, 30] after three years 20%, [16, 25, 30]
after five years 30%, [16, 30] and after six years 55%. [25, 30] Estimates of
publication probability after trial registration were available from five MRPs
(Fig. 5): [35, 38, 43, 47, 50] After two years the publication probability reached
approximately 30%, [35, 38, 43, 47, 50] after three years 50%, [38, 43, 47, 50] and
after five years approximately 60%. [38] Because of the low number of included
MRPs with data on follow-up, these estimates have to be interpreted cautiously.
Discussion
Principal findings
Overall, only about half of clinical and preclinical studies approved by RECs or
included in trial registries are published as full journal articles; however estimates
vary largely resulting in wide prediction intervals. For randomised controlled trials
a pooled overall proportion of studies published would be somewhat larger
(60.3%; 95% CI 45.4–73.6). Accordingly, prediction of the probability of
publication for a future study is very uncertain. We also found evidence for
dissemination bias in that studies with statistically significant results were more
likely to be published than those without (pooled OR 2.8; 95% CI 2.2–3.5). This
association is consistent with the finding that studies with positive results defined
as experimentally better or clinically relevant were more likely to be published
than studies with negative results though not reaching statistical significance
(pooled OR 3.1; 95% CI 0.9–11.0). In addition, phase-III trials – which might be
more successful than early-phase trials – were more likely to be published than
phase-II trials (pooled OR 2.0; 95% CI 1.6–2.5). Also, randomised controlled
trials which are considered as the ‘‘gold standard’’ design for a clinical study are
published more often than observational studies (pooled OR 2.0; 95% CI 1,3–3,3).
The reason for this finding could be that medical journals prefer to publish
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randomised controlled trials. But there may also be a tendency by study authors
not to not write up results of observational studies, in particular when they are
negative.
Strengths and weaknesses of this review
The findings of our systematic review are based on a thorough and comprehensive
literature search for the available evidence on dissemination bias. We considered
two types of MRPs which tracked studies from time of inception, thus including
39 individual MRPs evaluating more than 20,000 studies. For both types, the
evidence on dissemination bias was consistent suggesting that publications over
the last 20 years are an incomplete and biased subset of research findings. We
conducted our systematic review following a pre-specified protocol thus
preventing that any substantial post-hoc changes remain undisclosed. [6] Because
Fig. 4. Time to publication after ethics committee approval.
doi:10.1371/journal.pone.0114023.g004
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a registry for methodological reviews is not yet available, this protocol was not
prospectively registered, but previously published in an open-access journal. [6]
Our systematic review may have some limitations. We identified a large
number of MRPs but associations between study characteristics and journal
publication had not been reported in most of these publications. Therefore, not all
pre-specified subgroup analyses stated in the protocol could be performed. For
example, it was not possible to collate enough data on sex and rank of lead
investigator or language of publication to investigate these factors in association
with non-publication. We could not determine with certainty whether the MRP
authors carried out additional analyses that ultimately were not reported (as
authors were not contacted personally), thus selecting outcomes for publication.
Furthermore, the aggregated data for publication probability over time refer to
less than five studies at most time points. Accordingly, publication probabilities at
given time points have to be interpreted cautiously. The reported estimates can
only give a rough picture of the publication course after REC approval or trial
Fig. 5. Time to publication after trial registration.
doi:10.1371/journal.pone.0114023.g005
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registration. No standard methodology is available to assess study quality of the
types of research projects we considered for our review. Therefore, we devised a
tool to assess internal and external validity of the identified evidence. A sensitivity
analysis for MRPs with high risk of bias was planned initially [6] but not
performed due to the overall low quality of the identified MRPs. When we
calculated the overall proportion of studies published as journal articles we only
included studies with an arbitrarily defined minimum follow-up time of 24
months after study completion. Therefore, the proportion of studies published
may be underestimated in some MRPs because journal publication may have
occurred later. We included MRPs which investigated approved or on-going
rather than completed studies. A sensitivity analysis excluding those MRPs
showed that the proportion of studies published was similar. In addition, limited
data on potential risk factors (e.g., follow-up time, language of included studies)
made it impossible to further explore the large heterogeneity observed in our data.
We also acknowledge shortcomings (like inaccurate estimation of heterogeneity)
of random effects models meta-analysis - as carried out in our systematic review -
with a small number of included studies.
Comparison with other systematic reviews
In a Cochrane Methodology Review full publication of results initially presented
in abstracts was examined combining data from 79 MRPs; the weighted mean full
publication proportion was 44.5% (95% CI 43.9–45.1). [10] In this review,
survival analyses combining aggregated data resulted in an estimated publication
rate at nine years of 52.6% for all types of studies, 63.1% for randomised
controlled trials and 49.3% for other types of study designs. In addition, the
review showed a significant association of positive study results (defined as any
statistically significant result) with full publication. Other factors associated with
full publication were randomised trial study design and funded research. Despite
the different criteria for inclusion of MRPs (REC approval/trial registration versus
meeting presentation) their findings were consistent with our results.
The extent of dissemination bias in different types of research projects was also
investigated by Song et al. 2009. [57] The authors identified 12 MRPs that
followed up research from inception (studies approved by RECs or registered by
research funding bodies), four MRPs that included trials submitted to regulatory
authorities, 28 MRPs that assessed the fate of studies presented as conference
abstracts, and four MRPs that followed manuscripts submitted to journals. This
review concluded that dissemination bias related to direction of study results
mainly occurs before the presentation of findings at conferences and the
submission of manuscripts to journals. [57] A recent systematic review of studies
limited to randomised trials confirmed the existence of dissemination bias and
outcome reporting bias, although meta-analysis was not conducted due to the
differences between included studies. [58] In addition, a Cochrane Review
concluded that trials with positive findings are published more often and more
quickly than trials with negative findings. [59] Despite differences in types of
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study cohorts or MRPs included, all these reviews were consistent with our body
of evidence in concluding that a study with positive findings is more likely to be
published than a study with negative results. One might speculate that journals
prefer publishing reports with positive rather than non-positive results or that
investigators do not submit reports of studies with negative results.
Implications for policy makers and further research
Overall, the scientific literature represents an incomplete subset of research
findings. Due to the large heterogeneity, prediction of the probability of
publication for a single study is very uncertain. Our findings clearly confirm that
(non-)publication is not a random process and the likelihood of publication is
associated with the direction of study findings. When results are not published or
are published selectively based on the direction or the strength of the findings,
healthcare professionals and consumers of healthcare cannot base their decisions
on the full body of current evidence. This ignorance can lead to the use of
ineffective or harmful interventions and to waste of scarce health-care resources.
For example, when unpublished studies were included in a meta-analysis, the
antidepressant reboxetine was shown to have more adverse effects but no better
efficacy than placebo for treatment of major depression – a different finding from
that when only published studies were included. [60]
The inability to make evidence-informed decisions impacts the healthcare
system at various levels: First, dissemination bias is at odds with the ethical
responsibility towards patients to use all research to advance medical knowledge
and improve their care. Second, if treatment effects are overestimated this may
result in patients receiving treatments that may be more harmful or less
efficacious than previously believed. Finally, non-publication of studies results is
deleterious because a considerable part of the funds available for research are
spent without return. Additional costs include those incurred by health care
systems and individual patients who continue to pay for treatments that may not
be as effective or efficient as commonly thought. Although the full extent of
financial impact of non-publication of studies is currently unknown, the waste of
funds is likely to be high. [61, 62]
The creation of clinical trial registers and the prospective publication of detailed
study protocols with explicit outcome descriptions and analysis plans should help
to combat dissemination bias. The recent AllTrials campaign has proposed that
‘‘all trials past and present should be registered, and the full methods and the
results reported’’ (http://www.alltrials.net/). In addition, researchers should be
encouraged and supported to present their studies at conferences and to proceed
until full publication.
Nevertheless, dissemination bias exists and is currently invalidating findings in
systematic reviews and meta-analyses when only published studies are considered.
There is no excuse for study results to go unpublished and there is a huge public
health benefit from obtaining a complete picture of what has been found in all
studies to-date.
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